Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (453)	2/24/2005 11:36:32 AM
From: former_pgs	Read Replies (1) of 946

re: PK/PD for Xyotax I caught that post stating that a great fraction (>75%?) of the xyotax is sent out intact in the urine. I see two scenarios: 1) Such a great amount of excreted, intact Xyotax would mean that the drug is well below a reasonable, effective concentration in the blood. That would result in the Xyotax arm being absolutely ineffective in ST3, translating into a decrease of median survival for this arm compared to historical numbers. But on the contrary, the ST3 results suggest that, conservatively, both arms are showing median survivals that are greater than those published in the literature. That is not reasonably consistent with the hypothesized high fraction of intact excretion. 2) The other possibility is that the drug is cleared as Miljenko suggests. But then for it to achieve the effects shown in the clinic, the remaining 25% or so must be getting to the tumours very efficiently. Therefore, that suggests the targeting mechanism forwarded by CTIC must be working very, very, very effectively in vivo. I find this to be the relatively unlikely scenario.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next